Welcome to

He Ako Hiringa

Our mission is to contribute to creating equitable access to funded medicines, by providing education and updates to primary care clinicians.

Our resources are free to access. Log in and record your professional development using our CAPTURE function (at the end of each article).

He Ako Hiringa is intended for use by primary care health professionals - it is not a consumer information or education service. Consumers should seek advice from a health professional or visit www.healthnavigator.co.nz.

Our latest content

15 minutes to Read

Molnupiravir (Lagevrio) is an oral antiviral for treating patients with COVID-19 in the community.

Access criteria are the same as for nirmatrelvir/ritonavir (Paxlovid). Molnupiravir should only be used where nirmatrelvir/ritonavir is clinically inappropriate, as trial data suggest molnupiravir is much less effective. Read our article for details.

He Ako Hiringa, reviewed by Eamon Duffy
20 May 2022
60 minutes to Delve

Explore your prescribing further with EPiC Reflect Annual Report. This activity helps you to delve into your EPiC data, contemplate your prescribing, reflect on your current practice, and set goals and actions. Available as an editable PDF document, EPiC Reflect helps you to incorporate your learning into your everyday practice.

He Ako Hiringa
4 May 2022
1 minute to Read

Nirmatrelvir with ritonavir (Paxlovid), a new oral antiviral medicine for adults with COVID-19, is now available for community use. In people at higher risk of severe illness from COVID-19, treatment with Paxlovid has been shown to reduce the incidence of hospitalisation or death. However, for certain patients it will not be safe or appropriate to use Paxlovid. Prescriptions must be endorsed to confirm patients meet Pharmac access criteria.

2 May 2022
8 minutes to Read + 7 minutes to Delve

Since 1 April 2022, the oral antiviral combination nirmatrelvir/ritonavir (Paxlovid) has been listed on the Pharmaceutical Schedule for treating patients with COVID-19 in the community. This resource for prescribers and dispensing pharmacists links to Pharmac's access criteria and to comprehensive drug interaction guidance.

Eamon Duffy
31 March 2022

This short video explores what patients think about the move to Amgevita. We spoke to a group of seven New Zealanders living with arthritis to find out how they feel about changing from the biological reference medicine, Humira, to the new biosimilar medicine, Amgevita. 

He Ako Hiringa
14 April 2022

Thirsty for knowledge?

Subscribe to our newsletter to remain up to date with all our content and new features.